View Older Stories View More Recent Stories

Nov 21, 2022 04:05PM Biocept Reports Third Quarter 2022 Financial Results
Nov 18, 2022 08:02AM Biocept (BIOC) Appoints Quyen Dao-Haddock to its Board
Nov 18, 2022 08:00AM Biocept Appoints Financial Executive Quyen Dao-Haddock to its Board of Directors
Nov 16, 2022 08:00AM Biocept Announces Participation in an Investigator-Initiated Study to Better Understand the Development and Progression of Metastatic Breast Cancer to the Central Nervous System
Nov 10, 2022 04:05PM Biocept Reports Second Quarter 2022 Financial Results
Oct 19, 2022 08:00AM Biocept to Present at the LD Micro Main Event XV
Oct 17, 2022 08:00AM Biocept Expands Commercial Offering of CNSide™ Assay to Most Cancers that Metastasize to the Central Nervous System
Oct 14, 2022 08:00AM Biocept to Host KOL Webinar Today to Discuss its Proprietary CNSide™ Assay to Detect and Quantify Cancer that Metastasized to the Central Nervous System
Oct 6, 2022 08:00AM Biocept to Host Key Opinion Leader Webinar on October 14 to Discuss its Proprietary CNSide™ Assay to Detect and Quantify Cancer that Metastasized to the Central Nervous System
Aug 31, 2022 04:31PM Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 22, 2022 04:15PM Biocept Announces Receipt of Deficiency Notice from Nasdaq Regarding Requirement to Timely Quarterly Report on Form 10-Q
Aug 16, 2022 08:00AM Biocept Announces a Delay in the Filing of its Quarterly Report on Form 10-Q
Jun 27, 2022 08:00AM Biocept Appoints RSM as Independent Auditor
Jun 7, 2022 08:00AM Biocept to Hold Business Strategy Conference Call Today
May 23, 2022 04:05PM Biocept Reports First Quarter 2022 Financial Results
May 16, 2022 04:05PM Biocept Announces a Delay in the Filing of its Quarterly Report on Form 10-Q
Apr 8, 2022 04:05PM Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Apr 6, 2022 08:00AM Biocept Reports 2021 Fourth Quarter and Full Year Financial Results
Mar 31, 2022 06:15PM Biocept Reports Unaudited 2021 Revenue and Year-End Cash Balance
Mar 18, 2022 08:00AM Biocept to Report 2021 Fourth Quarter and Full Year Financial Results on March 31, 2022
Mar 8, 2022 08:17AM Biocept (BIOC) Appoints Philippe Marchand as Chief Operating Officer
Mar 8, 2022 08:17AM Biocept Appoints Philippe Marchand as Chief Operating Officer
Mar 4, 2022 08:00AM Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Feb 22, 2022 04:17PM Biocept Presentation at Molecular Medicine Tri-Con Meeting Highlights Potential of CNSide™ Assay to Support Development of Targeted Therapies for Metastatic Brain Cancer
Feb 16, 2022 04:05PM Biocept (BIOC) Appoints Samuel D. Riccitelli as Interim CEO and President, Antonino Morales as Interim CFO
Feb 16, 2022 04:05PM Biocept Appoints Samuel D. Riccitelli as Interim President and Chief Executive Officer and Antonino Morales as Interim Chief Financial Officer
Feb 10, 2022 08:17AM Biocept Names Darrell Taylor as Senior Vice President, General Counsel and Chief Compliance Officer
Jan 21, 2022 08:08AM Biocept (BIOC) Reports an Increase in COVID-19 RT-PCR Testing Volume with Spread of the Omicron Variant
Jan 21, 2022 08:00AM Biocept Reports an Increase in COVID-19 RT-PCR Testing Volume with Spread of the Omicron Variant
Jan 4, 2022 08:00AM Biocept to Present at the H.C. Wainwright BioConnect Virtual Conference on January 10
Dec 9, 2021 08:18AM Biocept's (BIOC) CNSide Cerebrospinal Fluid Assay Identifies Actionable HER2 Mutations in Patients with Breast Cancer that has Metastasized to the Brain
Dec 9, 2021 08:17AM Biocept’s CNSide Cerebrospinal Fluid Assay Identifies Actionable HER2 Mutations in Patients with Breast Cancer that has Metastasized to the Brain
Dec 1, 2021 08:47AM Quest Diagnostics Now Offers Biocept's Liquid Biopsy Test for Lung Cancer, Expanding its Menu of Advanced Cancer Diagnostics
Nov 22, 2021 08:17AM Biocept (BIOC) Launches Combined COVID-19 and Influenza Test
Nov 22, 2021 08:17AM Biocept Launches Combined COVID-19 and Influenza Test to Provide Answers During Peak Flu Season
Nov 18, 2021 08:18AM Biocept (BIOC) To Present CNSide Cerebrospinal Fluid Assay for Monitoring Treatment Response and Detects Actionable Biomarkers in Patients with Metastatic Breast Cancer
Nov 18, 2021 08:17AM Biocept’s CNSide Cerebrospinal Fluid Assay Aids in Monitoring Treatment Response and Detects Actionable Biomarkers in Patients with Metastatic Breast Cancer
Nov 18, 2021 08:17AM CORRECTING and REPLACING Biocept’s CNSide Cerebrospinal Fluid Assay Aids in Monitoring Treatment Response and Detects Actionable Biomarkers in Patients with Metastatic Breast Cancer
Nov 15, 2021 04:05PM Biocept Reports Third Quarter 2021 Financial Results
Nov 9, 2021 08:19AM Biocept (BIOC) Announces Study Shows its Switch-Blocker Technology Enhances Performance of Conventional PCR-Based Liquid Biopsy Assays in Detecting Rare Cancer Mutations
Nov 9, 2021 08:17AM Study Shows Biocept’s Switch-Blocker Technology Enhances Performance of Conventional PCR-Based Liquid Biopsy Assays in Detecting Rare Cancer Mutations
Nov 8, 2021 08:00AM Biocept to Report Third Quarter 2021 Financial Results and Host Investor Conference Call on November 15, 2021
Oct 6, 2021 08:00AM Biocept to Present at the LD Micro Main Event on October 13
Sep 22, 2021 08:17AM Biocept Implements COVID-19 Testing Program at Select California Community Colleges, Supporting Testing Needs for Students and Staff Amid Pandemic
Sep 21, 2021 08:17AM Biocept to Present Data at RAS-Targeted Drug Development Summit Showing Ability of Its Switch-BlockerTM Technology to Detect Rare Cancer Mutations
Sep 7, 2021 08:00AM Biocept to Present at Four Virtual Investor Conferences in September
Aug 31, 2021 08:00PM Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 19, 2021 08:34AM Biocept's (BIOC) CNSide Assay Identifies Tumor Cells and Actionable Treatment Biomarkers from Cerebrospinal Fluid in Patients with Metastatic Non-Small Cell Lung Cancer
Aug 19, 2021 08:34AM Biocept’s CNSide Assay Identifies Tumor Cells and Actionable Treatment Biomarkers from Cerebrospinal Fluid in Patients with Metastatic Non-Small Cell Lung Cancer
Aug 16, 2021 04:05PM Biocept Reports Second Quarter 2021 Financial Results
View More Recent Stories View Older Stories